“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers

Zeev Elkoshi Research and Development Department, Taro Pharmaceutical Industries Ltd, Haifa, IsraelCorrespondence: Zeev Elkoshi Email zeev.elkoshi@gmail.comAbstract: In an earlier publication, a binary classification of chronic diseases has been proposed. Chronic diseases were classified as &ldq...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Elkoshi Z
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	regulatory t cells lymphoma cancer alcohol consumption cigarette smoking checkpoints inhibitors high treg low treg inflammation autoimmune diseases immune escape Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e9a1efc1351e4bdc9181b2aee5038157
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9a1efc1351e4bdc9181b2aee5038157
record_format	dspace
spelling	oai:doaj.org-article:e9a1efc1351e4bdc9181b2aee50381572021-12-02T10:12:07Z“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers1178-7031https://doaj.org/article/e9a1efc1351e4bdc9181b2aee50381572020-05-01T00:00:00Zhttps://www.dovepress.com/ldquohigh-tregrdquo-inflammations-promote-most-non-hematologic-cancers-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Zeev Elkoshi Research and Development Department, Taro Pharmaceutical Industries Ltd, Haifa, IsraelCorrespondence: Zeev Elkoshi Email zeev.elkoshi@gmail.comAbstract: In an earlier publication, a binary classification of chronic diseases has been proposed. Chronic diseases were classified as “high Treg” or “low Treg” diseases depending on whether the pro-inflammatory or the anti-inflammatory arms of the immune response are deficient. The present work uses this model to analyze the interplay between cancer and the immune system, based on published literature. The work leans upon the etiology of alcohol and tobacco-related malignancies. The main conclusions are: triggers of specific “high Treg” immune reaction promote most non-hematologic cancers, whereas triggers of “low Treg” immune reaction promote lymphomas. The opposite is also true: triggers of specific “high Treg” immune reaction suppress lymphoma, whereas triggers of “low Treg” immune reaction suppress non-hematologic cancers. Both lymphoma and autoimmune diseases are “low Treg” conditions. For this reason, both are promoted by the same panel of “low Treg” bacteria and parasites and are inhibited by “high Treg” triggers. For example, alcohol consumption, a “high Treg” trigger, protects against lymphoma and autoimmune hypothyroidism. In addition, the same immune-modulatory drugs are effective in the treatment of both lymphoma and autoimmune diseases. Like other cancers, lymphoma transforms from a “low Treg” type at early stage of the disease into a “high Treg” type at advanced stages. However, lymphoma is distinguished from most other cancers by the length of time it dwells at an indolent “low Treg” state (many years) before lymphoma cells sensitivity to transforming growth factor-beta is impaired. This impairment stimulates the switch from “low Treg” into “high Treg” response and results in immune escape. The application of this analysis to the pharmacological activity of checkpoint inhibitors forecasts that checkpoint inhibitors would not be effective in low-grade, indolent lymphomas. As of now, checkpoint inhibitors are approved for the treatment of advanced lymphoma only.Keywords: regulatory T cells, lymphoma, cancer, alcohol consumption, cigarette smoking, checkpoint inhibitors, high Treg, low Treg, inflammation, autoimmune diseases, immune escapeElkoshi ZDove Medical Pressarticleregulatory t cellslymphomacanceralcohol consumptioncigarette smokingcheckpoints inhibitorshigh treglow treginflammationautoimmune diseasesimmune escapePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 13, Pp 209-221 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	regulatory t cells lymphoma cancer alcohol consumption cigarette smoking checkpoints inhibitors high treg low treg inflammation autoimmune diseases immune escape Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	regulatory t cells lymphoma cancer alcohol consumption cigarette smoking checkpoints inhibitors high treg low treg inflammation autoimmune diseases immune escape Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Elkoshi Z “High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers
description	Zeev Elkoshi Research and Development Department, Taro Pharmaceutical Industries Ltd, Haifa, IsraelCorrespondence: Zeev Elkoshi Email zeev.elkoshi@gmail.comAbstract: In an earlier publication, a binary classification of chronic diseases has been proposed. Chronic diseases were classified as “high Treg” or “low Treg” diseases depending on whether the pro-inflammatory or the anti-inflammatory arms of the immune response are deficient. The present work uses this model to analyze the interplay between cancer and the immune system, based on published literature. The work leans upon the etiology of alcohol and tobacco-related malignancies. The main conclusions are: triggers of specific “high Treg” immune reaction promote most non-hematologic cancers, whereas triggers of “low Treg” immune reaction promote lymphomas. The opposite is also true: triggers of specific “high Treg” immune reaction suppress lymphoma, whereas triggers of “low Treg” immune reaction suppress non-hematologic cancers. Both lymphoma and autoimmune diseases are “low Treg” conditions. For this reason, both are promoted by the same panel of “low Treg” bacteria and parasites and are inhibited by “high Treg” triggers. For example, alcohol consumption, a “high Treg” trigger, protects against lymphoma and autoimmune hypothyroidism. In addition, the same immune-modulatory drugs are effective in the treatment of both lymphoma and autoimmune diseases. Like other cancers, lymphoma transforms from a “low Treg” type at early stage of the disease into a “high Treg” type at advanced stages. However, lymphoma is distinguished from most other cancers by the length of time it dwells at an indolent “low Treg” state (many years) before lymphoma cells sensitivity to transforming growth factor-beta is impaired. This impairment stimulates the switch from “low Treg” into “high Treg” response and results in immune escape. The application of this analysis to the pharmacological activity of checkpoint inhibitors forecasts that checkpoint inhibitors would not be effective in low-grade, indolent lymphomas. As of now, checkpoint inhibitors are approved for the treatment of advanced lymphoma only.Keywords: regulatory T cells, lymphoma, cancer, alcohol consumption, cigarette smoking, checkpoint inhibitors, high Treg, low Treg, inflammation, autoimmune diseases, immune escape
format	article
author	Elkoshi Z
author_facet	Elkoshi Z
author_sort	Elkoshi Z
title	“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers
title_short	“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers
title_full	“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers
title_fullStr	“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers
title_full_unstemmed	“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers
title_sort	“high treg” inflammations promote (most) non-hematologic cancers while “low treg” inflammations promote lymphoid cancers
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/e9a1efc1351e4bdc9181b2aee5038157
work_keys_str_mv	AT elkoshiz ldquohightregrdquoinflammationspromotemostnonhematologiccancerswhileldquolowtregrdquoinflammationspromotelymphoidcancers
_version_	1718397554215878656

&ldquo;High Treg&rdquo; Inflammations Promote (Most) Non-Hematologic Cancers While &ldquo;Low Treg&rdquo; Inflammations Promote Lymphoid Cancers

Ejemplares similares

“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers